Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aim, Cellcentric, CNS, Entrada, Fluoguide, Index, Ingeneron, Innovent.
Based on previous studies that have demonstrated the potential of growth hormone-releasing hormone receptor (GHRH-R) antagonists to modulate immune responses to bleomycin lung injury, researchers from the University of Miami and affiliated organizations aimed to evaluate the potential of the GHRH-R antagonist MIA-602 in a mouse model of rVSV-SARS-CoV-2-induced pulmonary dysfunction and heart injury.
Researchers from the University of Queensland discovered that senolytic therapies can suppress long-COVID neuropathology and long-term disorders caused by viral infections by reducing senescent cells, thereby reducing inflammation. Published Nov. 13, 2023, in Nature, the study examined the use of human pluripotent stem cells to generate small mini human brain organoids to screen for antiaging interventions called senolytics that selectively eliminate senescent cells that accumulate with age, lead author Julio Aguado told BioWorld.
Additional early-stage research and drug discovery news in brief, from: Athira Pharma, Chroma Medicine, Cognition Therapeutics, Geovax Labs, Longhorn Vaccines and Diagnostics LLC, Omega Therapeutics.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Astrazeneca, Atreca, Genetex, Graphite, Inhalon, Lenz, Lilly, Point.
The National Institute of Allergy and Infectious Diseases (NIAID) is set to conduct a phase I trial with Tonix Pharmaceuticals Holding Corp.’s TNX-1800 (recombinant horsepox virus, live vaccine), a vaccine candidate to protect against COVID-19.
RSS
